Matthew Harding, Ph.D has 30+ years of experience in pharmaceutical R&D. Matt is a member of the RA Ventures team and is Vice President, Translational Research for CarnotPharma LLC, the RA Ventures internal R&D entity. Programs initiated within CarnotPharma LLC include Imbria Pharmaceutical’s IMB-101 and IMB-102 molecules. Matt was one the original scientists to join Vertex Pharmaceuticals at its founding in 1989. He has broad experience across multiple therapeutic areas in roles spanning discovery research to proof of concept early clinical development. Prior to Vertex, Matt was an Assistant Professor in the Division of Organ Transplantation and Immunology at Yale Medical School. He holds a Ph.D in immunology from the University of Connecticut.